At a glance
ClinicalIndex Comparison RecordPhase 2Active· 19 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Pembrolizumab in Untreated Extranodal, NK/T Cell Lymphoma, Nasal Type
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis) and NK/T-Cell Lymphoma of Nasopharynx (Diagnosis). Active but no longer recruiting, targeting 19 participants across 10 sites.
Detailed Summary
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201920202021202220232024202520262027
First PostedNov 2018
Enrollment StartNov 2018
Primary CompletionJun 2025
TodayJul 2026
Study CompletionNov 2026
First PostedNov 2, 2018
Enrollment StartNov 9, 2018
Primary CompletionJun 15, 2025
Study CompletionNov 1, 2026
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 7.7 years ago
Interventions
Pembrolizumabdrug
200mg IVPB every 3 weeks